Evidence map›Paper›PMID 41013675›Full record

ArticleTrials2025

Hypothermic oxygenated perfusion (HOPE) against cancer recurrence after liver transplantation for hepatocellular carcinoma-study protocol for an international multicenter randomized controlled trial (HOPE4Cancer).

Janina Eden, Philip C Müller, Christoph Kuemmerli, Florian Peters, Tanja Litke, Anne Kranich, Andreas E Kremer, Stefanie von Felten, Philipp Dutkowski, HOPE4Cancer Trial Investigators

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06717919 (Hypothermic Oxygenated Perfusion), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06717919 phase4recruitingnot on this map

Hypothermic Oxygenated Perfusion (HOPE) Against Cancer Recurrence in HCC Liver Transplantation - International Multicentre Parallel Group Interventional RCT

TypeinterventionalSponsorPhilipp DutkowskiRan2025 to 2028Enrolled220ConditionsLiver Transplantation, HCC, Oncological OutcomesArmsHypothermic oxygenated perfusion, Conventional cold storage
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Janina Eden *Department of Surgery, Section of HPB Surgery and Liver Transplantation, University of Groningen and University Medical Center Groningen, Groningen, the Netherlands.
Philip C Müller *Department of Surgery, Clarunis University Digestive Health Care Center, University Hospital Basel, Basel, Switzerland.
Christoph KuemmerliDepartment of Surgery, Clarunis University Digestive Health Care Center, University Hospital Basel, Basel, Switzerland.
Florian PetersUniversity of Basel, Basel, Switzerland.
Tanja LitkeUniversity of Basel, Basel, Switzerland.
Anne KranichOncoDrugConsult BV, Amsterdam, the Netherlands.
Andreas E Kremer *Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
Stefanie von Felten *Department of Biostatistics, Epidemiology, Biostatistics, and Prevention Institute, Faculty of Medicine, University of Zurich, Zurich, Switzerland.
Philipp Dutkowski *Department of Surgery, Clarunis University Digestive Health Care Center, University Hospital Basel, Basel, Switzerland. philipp.dutkowski@clarunis.ch.
HOPE4Cancer Trial Investigators

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 33IC30_221622
6 · The paper itself

Abstract

backgroundA frequent and increasing indication for liver transplantation (LT) is hepatocellular carcinoma (HCC). However, despite strict selection criteria, HCC recurrence after LT occurs in a relevant proportion of patients and is associated with an unfavorable prognosis. Hypothermic oxygenated perfusion (HOPE) is a novel machine liver perfusion approach to optimize liver grafts before implantation and has been suggested to decrease graft inflammation with potential anti-cancer effects.

methodsHOPE4Cancer is an international, multicentric, parallel group, randomized controlled trial comparing HOPE performed after initial cold storage (intervention) with conventional cold storage alone (control) in a 1:1 allocation ratio. Adult recipients with proven HCC will be included for transplantation of a DBD (donation after brain death) Liver graft. The minimum perfusion duration is defined at 2 h and perfusion is generally continued until the recipient hepatectomy is completed. The conventional cold storage at 4 °C will be performed with a precooled preservation solution according to the local standard of care. The primary endpoint is defined as post-transplant HCC recurrence-free survival, i.e., the time interval a patient is alive without HCC recurrence after transplantation. Secondary endpoints are the single components of the events considered for the primary outcome (i.e., HCC recurrence, HCC-related death, death from any other causes than HCC), circulating tumor DNA, high-mobility-group-protein B1 in the blood, the Rejection Activity index, and the number of liver-related complications experienced by the patient. DISCUSSION: HOPE4Cancer investigates if cold storage plus end-ischemically applied HOPE in DBD LT is superior to conventional cold storage of liver grafts in terms of post-transplant HCC recurrence-free survival. The results will indicate for the first time whether ex situ HOPE before transplant has an anti-cancer potential compared to transplantation of un-perfused livers.

trial registrationClinicalTrials.gov NCT06717919. Registered on December 5, 2024.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsLiver TransplantationNeoplasm Recurrence, LocalOrgan PreservationPerfusionAdultHumansMulticenter Studies as TopicRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeHepatocellular carcinomaLiver transplantationOrgan preservationPerfusion

Identifiers

PMID41013675
PMCPMC12465341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.